Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast CancerOlivia Pagani, Prudence A. Francis, Hervé Bonnefoi et al.|New England Journal of Medicine|2014Cited by 751
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast CancerPrudence A. Francis, Meredith M. Regan, Olivia Pagani et al.|New England Journal of Medicine|2018Cited by 684
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trialMarco Colleoni, Joanna Vermeij, Weixiu Luo et al.|The Lancet Oncology|2017Cited by 122
Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a “standard chemotherapy regimen”: The CASA randomized trialDiana Crivellari, Aron Goldhirsch, Kathryn P. Gray et al.|The Breast|2013Cited by 56
Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL)Daniel Betticher, David C. Linch, John Radford et al.|Annals of Oncology|2006Cited by 42